ENvue Medical Inc. (FEED) is a pioneering healthcare technology company that specializes in the development of cutting-edge medical devices and integrated software solutions aimed at enhancing patient care management. By leveraging innovation to optimize health outcomes and streamline recovery processes, ENvue is well-positioned to capitalize on substantial growth opportunities within the dynamic healthcare landscape. With a strong product pipeline and strategic collaborations, the company represents a compelling investment for institutional investors interested in the future of medical devices and digital health advancements.
| Revenue (TTM) | $2.18M |
| Gross Profit (TTM) | -271,000 |
| EBITDA | $-12.50M |
| Operating Margin | -568.00% |
| Return on Equity | -59.50% |
| Return on Assets | -20.20% |
| Revenue/Share (TTM) | $1.52 |
| Book Value | $8.65 |
| Price-to-Book | 0.13 |
| Price-to-Sales (TTM) | 1.98 |
| EV/Revenue | 1.393 |
| EV/EBITDA | 0.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -36.30% |
| Shares Outstanding | $9.30M |
| Float | $6.09M |
| % Insiders | 20.92% |
| % Institutions | 3.39% |
Volatility is currently contracting
Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland
TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase agreement (“ELOC”) with an institutional investor providing the Company with an equity facility for up to $50 million in capital (the “Facility”), subject to the terms and conditions of the agreement, including the receipt of stockholder approval.
TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.
Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation
Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance Leadership and $320 Million in Executed Financings and M&A, Respectively TYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that Zeev Rotstein, M.D.
ENvue Targeting Combined $10 Billion+ Enteral Feeding and Vascular Access Market Opportunity* ENvue Drive™ Demonstration Marks First Step Toward a New Generation of Intelligent Bedside Procedures and Integrates ENvue's Proprietary AI Navigation Software, Ask Oscar™ TYLER, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced the successful development and demonstration of the first prototype of ENvue Drive™, which the Company believes is the first next-generation robotic-assisted tool built within the ENvue electromagnetic navigation platform ecosystem, designed to integrate artificial intelligence, real-time navigation, and robotic-assisted procedural execution into a unified clinical workflow. A demonstration video highlighting the ENvue Drive prototype, including integrated navigation, artificial intelligence, and robotic-assisted advancement capabilities, is available here: http://envue.com/ask-oscar/#video.
MANAUS, Brazil, June 17, 2026 (GLOBE NEWSWIRE) -- Brazil Potash Corp. (“Brazil Potash” or the “Company”) (NYSE-American: GRO), a mineral exploration and development company advancing the Autazes potash project in Amazonas State, Brazil (the “Autazes Project” or “Project”), is pleased to announce the award of a second Front-End Engineering Design (“FEED”) contract for mine shafts and underground development to WSP UK Ltd., with Redpath Deilmann (“Redpath”) as subconsultants for the mine shafts scope.
NEWARK, Calif. & WARSAW, Poland--(BUSINESS WIRE)-- #EnergyIndependence--Ohmium International Inc., a leading manufacturer of high-efficiency, modular Proton Exchange Membrane (PEM) electrolyzers, and Hynfra P.S.A., a prominent green hydrogen and green ammonia project developer, today announced the signing of a master cooperation agreement to advance green hydrogen projects in Mauritania, Jordan, and Oman. The cooperation agreement covers the projects' Front-End Engineering and Design (FEED) stage and establishes the.
AI-based platform, ‘Ask Oscar™', to accelerate adoption of ENvue's Navigation Platform and enable clinicians to train independently and reduce implementation barriers
Second ENvue Navigation Platform Deployed Within the Same Health System Reflects the Clinical Confidence in Company's Real-Time Guided Feeding Tube Placement for Patients Second ENvue Navigation Platform Deployed Within the Same Health System Reflects the Clinical Confidence in Company's Real-Time Guided Feeding Tube Placement for Patients
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FEED and any ticker you trade — then tracks every position and per-strategy win rate.
